Literature DB >> 31325588

Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease.

Stephanie M Cizek1, Javier El-Bietar2, Jeremy Rubinstein2, Christopher Dandoy2, Gregory H Wallace2, Adam Nelson2, Pooja Khandelwal2, Kasiani C Myers2, Holly R Hoefgen3.   

Abstract

Vulvovaginal graft-versus-host disease (GVHD) is an underdiagnosed and poorly recognized complication of hematopoietic stem cell transplantation (HSCT). Previous studies have reported findings restricted to predominantly adult populations. We report a case series of pediatric and young adult vulvovaginal GVHD, which was identified in 19 patients (median age, 11.8 years; range, 2.4 to 21.9 years) out of a total 302 female patients who underwent transplantation over an 8-year period at a pediatric HSCT center. The majority of patients had concomitant nongenital GVHD; only 1 patient had isolated vulvovaginal GVHD. The median time from bone marrow transplantation to diagnosis of vulvovaginal GVHD was 30 months (range, 2.3 to 97.5 months). A high percentage of the patients in our series were without vulvar or vaginal symptoms (n = 8; 42%), even though 17 patients (89%) presented with grade 3 disease based on current adult grading scales. Vulvar examination findings most frequently included interlabial and clitoral hood adhesions (89%), loss of architecture of the labia minora or clitoral hood (42%), and skin erosions or fissures (37%). Only 5 patients underwent a speculum exam, none of whom had vaginal GVHD. Examination findings of primary ovarian insufficiency (POI) can overlap with those of GVHD, and 6 patients (32%) in our cohort were diagnosed with POI. Only 1 patient was on systemic hormone replacement therapy at the time of vulvovaginal GVHD diagnosis. The majority of patients (n = 16) were treated with topical steroid therapy, with a median time to response of 43 days. Five patients (26%) had a complete response to therapy, and 10 patients (53%) had a partial response. This case series provides valuable insight into pediatric and young adult vulvovaginal GVHD and highlights the need for increased screening for vulvar disease in this population.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GVHD; Gynecology; Pediatric; Survivorship; Vaginal; Vulvar

Year:  2019        PMID: 31325588     DOI: 10.1016/j.bbmt.2019.07.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

Review 1.  Pediatric Vulvovaginal Graft-Versus-Host Disease: A Retrospective Cohort Study and Literature Review.

Authors:  Tazim Dowlut-McElroy; Stephanie Shin; Elizabeth Stepanek; David Jacobsohn; Veronica Gomez-Lobo
Journal:  J Pediatr Adolesc Gynecol       Date:  2022-04-25       Impact factor: 2.046

2.  COVID, Science, Vaccines, and Public Trust.

Authors:  Paula J Adams Hillard
Journal:  J Pediatr Adolesc Gynecol       Date:  2020-12       Impact factor: 1.814

Review 3.  Early Detection of Vulvovaginal Graft-Versus-Host Disease: An Integrative Review.

Authors:  Payton L Ten Hagen; Christi Bowe; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2021-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.